Clinical Trial on Sambazon Açaí Part of Mounting Evide
the Berry’s Heart Health Benefits
Emerging Science Results from Pilot Study Earned Top Honors During National Health Conference
January 26, 2010 11:34 AM Eastern Time
SAN CLEMENTE, Calif.--(EON: Enhanced Online News)--A new clinical trial investigating the health benefits of açaí, the antioxi
rich berry, is adding to the emerging scientific evidence of the fruit’s ability to potentially reduce some metabolic risk factors associat
cardiovascular disease, diabetes and stroke. The latest study won top honors during the Scripps Center for Integrative Medicine on
revealed promising initial results for using Sambazon açaí to improve vascular health, lower fasting blood sugar levels, and lower ba
“This pilot study demonstrated the ability of the Sambazon açaí pulp product to significantly lower several markers of cardiovascular
short period of time. Given these promising results, and the biologically active components in the açaí fruit, further study is merited,”
Udani, MD, CEO and Medical Director of Medicus Research, a leading contract research organization with functional food experie
Medicus Research recently conducted a pilot study with 10 slightly overweight, but healthy adult male and female participants (repr
American population). Each study participant consumed 100 grams of Sambazon® açaí frozen fruit pulp twice daily for one month.
measured participants’ baseline fasting plasma glucose, plasma insulin levels, lipid levels (total cholesterol, HDL, LDL, triglycerides)
C-reactive protein and blood pressure. After 30 days of consuming Sambazon® açaí, participants’ fasting glucose, insulin, total cho
(bad cholesterol) were significantly reduced, as compared to the baseline. In addition, post-prandial (between meals) increases in bl
were significantly reduced.
“While additional research is needed, this pilot study suggests that in otherwise healthy, overweight adults, daily consumption of Sa
reduces several markers of metabolic syndrome associated